161/344US=49-D / Câncer
Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase ron in tumor growth and metastasis. In: Woude GFV, Klein G. Advances in cancer research. v.100. Amsterdam: Elsevier, 2008. p. 1-33. ISBN 978-0-12-374358-9.

RECEPTOR MET; TIROSINA-QUINASE; CRESCIMENTO TUMORAL; METASTASE; CANCER; RON. ESTRUTURA; RON. FUNCAO; RON (REGIAO ORGANIZADORA DE NUCLEOLO); MACROFAGOS; TRANSICAO EPITELIAL MESENQUIMAL; TUMORIGENESE; ANGIOGENESE; EXPRESSAO EM TUMORES HUMANOS; CANCER DE MAMA; CANCER DE PROSTATA; CANCER DE PANCREAS; CANCER DE RIM; CANCER DE BEXIGA; CANCER DE OVARIO; CANCER DE PULMAO; CANCER GASTROINTESTINAL; CANCER DE FIGADO; CANCER. TERAPIA


162/344US=49-D / Câncer
Linger RMA, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. In: Woude GFV, Klein G. Advances in cancer research. v.100. Amsterdam: Elsevier, 2008. p. 35-83. ISBN 978-0-12-374358-9.

TAM; TIROSINA QUINASES; FUNCOES BIOLOGICAS; SINALIZACAO; TERAPEUTICA; CANCER HUMANO; BIOLOGIA MOLECULAR


163/344US=49-E / Câncer
Orian-Rousseau V, Ponta H. Adhesion proteins meet receptors: a common theme?. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2008. p. 63-92. ISBN 978-0-12-374359-6.

PROTEINAS DE ADESAO; RECEPTORES; CADERINAS; NEUROPILINA; INTEGRINAS; RTK; CD44; RECEPTOR SINALIZADOR WNT


164/344US=49-E / Câncer
Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2008. p. 127-248. ISBN 978-0-12-374359-6.

SUSCEPTIBILIDADE DE MALIGNIDADES; GLUCOCORTICOIDES; APOPTOSE; RECEPTOR DE GLICOCORTICOIDE; IMUNOSSUPRESSAO


165/344US=53 / Biol/Mol
Sandberg A, Stone JF. Key mechanisms and pathways. In: ___. The genetics and molecular biology of neural tumors. New Jersey: Humana Press, 2008. p. 431-43. ISBN 978-1-59745-510-7.

TUMORES NEURAIS; VIAS MOLECULARES; TP53; RB; WNT; SHH; EGFR; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; TELOMERES; TELOMERASE; EPIGENETICA; CICLO CELULAR; APOPTOSE


166/344US=64 / Câncer
Jiménez-Zepeda VH, Stewart AK. Fibroblast growth, factor receptor 3 and multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 365-78. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

CRESCIMENTO DE FIBROBLASTOS; RECEPTOR DO FACTOR DE 3; MIELOMA MULTIPLO; TRANSLOCACOES CROMOSSOMICAS


167/344US=65 / Biol/Mol
D'Alessio S, Blasi F. The urokinase plasminogen activator receptor as a target for cancer therapy. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 223-43. ISBN 978-0-387-69056-8.

RECEPTOR UROQUINASE; ATIVADOR DO PLASMINOGENIO; TERAPIA DO CANCER; SISTEMA UPA/UPAR; TRANSDUCAO DE SINAL; MOTILIDADE CELULAR; PROLIFERACAO CELULAR; CANCER; ESTRATEGIAS TERAPEUTICAS ANTISENSE; APOPTOSE


168/344US=65 / Biol/Mol
Hillig T, Engelholm LH, Behrendt N. The endocytic collagen receptor, uPARAP/Endol180, in cancer invasion and tissue remodeling. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 245-58. ISBN 978-0-387-69056-8.

RECEPTOR DO COLAGENO ENDOCITICA; UPARAP/ENDOL180; CANCER; REMODELACAO DO TECIDO


169/344US=65 / Biol/Mol
Degryse B. The urokinase receptor and integrins constitute a cell migration signalosome. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 451-74. ISBN 978-0-387-69056-8.

RECEPTOR DE UROCINASE; INTEGRINAS; MIGRACAO CELULAR


170/344US=65 / Biol/Mol
Jacobsen B, Kjaergaard M, Gardsvoll H, Ploug M. Structure and inhibition of the urokinase-type plasminogen activator receptor. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 699-719. ISBN 978-0-387-69056-8.

ATIVADOR DO PLASMINOGENIO TIPO UROQUINASE; UPAR; ANTICORPOS MONOCLONAIS; ANTAGONISTAS PEPTIDICOS


171/344US=67 / Biol/Mol
Sundermeyer ML, Bellacosa A, Meropol NJ. Molecular targeting of colorectal cancer: an idea whose time has come. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 117-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER COLORRETAL; SEGMENTACAO MOLECULAR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR


172/344US=67 / Biol/Mol
Goel A, Kozuch P. Molecularly targeted therapy in pancreatic cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 211-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PANCREAS; TERAPIA ALVO MOLECULAR; BEVACIZUMABE; CETUXIMABE; ERLOTINIBE; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); TERAPIA ANTI-ANGIOGENICA


173/344US=67 / Biol/Mol
Ho C, Davies AM, Lara PN, Gautschi O, Mach PC, Gumerlock PH, Gandara DR. Untargeted use of targeted therapy: a dilemma in non-small cell lung cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 227-40. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PULMAO DE CELULAS NAO-PEQUENAS; TERAPIA-ALVO; EGFR; VEGF; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL


174/344US=67 / Biol/Mol
Azad NS, Sarosy G, Kohn EC. Molecular targets in ovarian cancer and endometrial cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 291-308. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE OVARIO; CANCER ENDOMETRIAL; ALVOS MOLECULARES; TIROSINA-QUINASES; EGFR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); ONCOGENE; GENES SUPRESSORES DE TUMOR


175/344US=67 / Biol/Mol
Mendelsohn J. Development of a targeted treatment for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 559-71. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER; TERAPIA; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; CETUXIMABE; TIROSINA QUINASE; ANTICORPO MONOCLONAL C225


176/344US=67 / Biol/Mol
Champaneria MC, Modlin IM, Latich I, Bornschein J, Drozdov I, Kidd M. Somatostatin analogue therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 585-637. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

TERAPIA ANALOGA DA SOMATOSTATINA; ACROMEGALIA; CARCINOIDE; SINDROME CARCINOIDE; HORMONIO DE CRESCIMENTO; LUTECIO; OCTREOTIDE; NEUROENDOCRINO; PROLIFERACAO; CINTILOGRAFIA; RECEPTOR DE SOMATOSTATINA; SOMATULINA; TUMOR; ITRIO


177/344US=67 / Biol/Mol
Kitzen JJEM, de Jonge MJA, Verweij J. How to define treatment sucess or failure if tumors do not shrink: consequences for trial design. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 657-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

MARCADOR SUBSTITUTO; TECIDO SUBSTITUTO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DA FARNESIL TRANSFERASE; SELECAO DE PACIENTE; IMAGEM; PROJETO DESCONTINUACAO RANDOMIZADO; INDICE DE MODULACAO DO CRESCIMENTO; TAXA DE PROGRESSAO; TAXA LIVRE DE PROGRESSAO


178/344US=69 / Câncer
Wedgwood A, Younes A. Targeted therapy in lymphoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 157-82. ISBN 978-1-60327-423-4.

TERAPIA-ALVO NO LINFOMA; ANTICORPO; LINFOMA; ANTIGENO; RECEPTOR; INIBIDOR; QUINASE


179/344US=69 / Câncer
Davies M, Patel S, Kim KB. Targeted therapy in melanoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 183-211. ISBN 978-1-60327-423-4.

TERAPIA-ALVO EM PACIENTES COM MELANOMA; MELANOMA; TRANSDUCAO DE SINAL; QUINASE DO RECEPTOR; B-RAF; N-RAS; PTEN; MAP QUINASE; NFKB; ANTIOGENESIS; IMMUNOTARGETING


180/344US=8 / Dermatologia
Halaban R, Hebert DN, Fisher DE. Biology of melanocytes. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editores. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2008. p. 127-48. ISBN 978-0-07138076-0.

BIOLOGIA DOS MELANOCITOS; CELULAS DE PIGMENTO; LOCALIZACAO DOS MELANOCITOS; FUNCAO DOS MELANOCITOS; SINTESE DE MELANINA; DISTRIBUICAO DE MELANOSSOMAS; TRANSPORTE DE MELANOSSOMAS; BIOSSINTESE; MELANOCORTINA; RECEPTOR DA MELANOCORTINA; REGULADORES DO MELANOCITO; EXPRESSAO ESPECIFICA DE GENE; FATORES DE CRESCIMENTO; TRANSDUCAO DE SINAL


Primeira | Anterior | Próxima | Última